Adsorption of cold agglutinins with rabbit red blood cells

Cobaugh, Adam

doi:10.21307/immunohematology-2018-008

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To ascertain the presence of CAs, serum/plasma samples were processed using rabbit erythrocyte stroma (RESt®, Immucor), which absorbs anti‐I antibodies. 5 Adult O red blood cell (RBC) reagents (Ortho® BioVue™ Screen J; RBC‐I, RBC‐II, RBC‐III) were purchased from Ortho Clinical Diagnostics (Raritan). Newborn baby O RBCs were collected from residual blood samples.…”

Section: Methodsmentioning

confidence: 99%

“…Serum samples were obtained from patient 1 on Day 11 post‐admission and cryopreserved at −20°C, whereas plasma samples were obtained from patient 2 on Day 32. To ascertain the presence of CAs, serum/plasma samples were processed using rabbit erythrocyte stroma (RESt®, Immucor), which absorbs anti‐I antibodies 5 . Adult O red blood cell (RBC) reagents (Ortho® BioVue™ Screen J; RBC‐I, RBC‐II, RBC‐III) were purchased from Ortho Clinical Diagnostics (Raritan).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cold agglutinin anti‐I antibodies in two patients with COVID‐19

Imoto

Yoshioka

Nakagawa

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Cold agglutinin syndrome (CAS) is associated with various diseases. Several studies of CAS associated with coronavirus disease 2019 (COVID‐19) reported hemolytic anemia and thrombosis; however, the clinical significance of cold agglutinins (CA) in patients with COVID‐19 is unclear. Here, we present two cases of CA identified in the context of COVID‐19 without hemolytic anemia and clotting. Case report and Discussion Two patients with no known risk factors for CA were diagnosed with COVID‐19; peripheral blood smears reveal red blood cells (RBCs) agglutination. These patients showed a high CA titer. We confirmed retrospectively that the CA was an anti‐I antibody. The two COVID‐19 cases with a high CA titer showed no hemolysis or thrombosis. Mycoplasma pneumoniae is known to cause CAS, but not all patients who have a high CA titer show hemolysis. Coagulation abnormalities are documented in severe COVID‐19 cases. Although CA increases the risk of thrombosis in those with lymphoproliferative diseases, the role of anti‐I antibodies in COVID‐19 is unclear. The impact of CAS on clinical presentations in COVID‐19 remains a matter of verification. Conclusions A high CA titer was identified in COVID‐19 patients without hemolytic anemia and clotting. Anti‐I antibodies were identified. Further studies are required to clarify the pathophysiology of CA in COVID‐19.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Cold agglutinin anti‐I antibodies in two patients with COVID‐19

Imoto

Yoshioka

Nakagawa

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

Human red blood cell stroma: an alternative to traditional allogeneic adsorption methods

Wilson

Branch

2019

Transfusion

View full text Add to dashboard Cite

show abstract

Daudi cell stroma: An alternative to dithiothreitol to resolve daratumumab interference in pretransfusion testing

2020

View full text Add to dashboard Cite

Background Treatment of red blood cells with dithiothreitol (DTT) or trypsin effectively denatures CD38; however, this treatment damages other antigens, some of which are of clinical importance. Thus, other avenues to deplete daratumumab (DARA) from plasma samples should be explored. Study Design and Methods The Daudi B‐cell line was found to express high levels of CD38 and was sonicated in a sonication buffer to achieve complete cell lysis. The resulting stroma preparation was centrifuged at 20 000g for 20 minutes and then mixed with 250 μL of DARA–plasma and incubated for 10 minutes at 37°C. The stroma–DARA–plasma mixture was centrifuged again, and the supernatant was collected and subjected to four additional rounds of adsorption with fresh stroma. DARA‐depleted plasma was tested by gel indirect antiglobulin test (IAT). Results CD38 expression on Daudi cells was confirmed by flow cytometry. Gel IAT analysis showed that the incubation of plasma from DARA‐treated patients with Daudi cells stroma resulted in a significant depletion of DARA but allowing detection of other alloantibodies of interest such as anti‐K, anti‐Yta, and anti‐Gya. Conclusions Daudi cell stroma is inexpensive, easy to prepare in large batches, and can be used as an off‐the‐shelf reagent. Incubation of plasma from DARA‐treated patients with Daudi cell stroma can efficiently overcome DARA interference in serologic testing without affecting DTT‐ or trypsin‐sensitive antigens.

show abstract

Adsorption of cold agglutinins with rabbit red blood cells

Cited by 4 publications

References 5 publications

Cold agglutinin anti‐I antibodies in two patients with COVID‐19

Cold agglutinin anti‐I antibodies in two patients with COVID‐19

Human red blood cell stroma: an alternative to traditional allogeneic adsorption methods

Daudi cell stroma: An alternative to dithiothreitol to resolve daratumumab interference in pretransfusion testing

Contact Info

Product

Resources

About